Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures

Objective Lusutrombopag is a thrombopoietin receptor agonist that improves thrombocytopenia in patients with chronic liver disease scheduled to undergo invasive procedures. However, information on the efficacy of repeated lusutrombopag treatment and factors associated scarce. We analyzed response lusutrombopag. Methods Thirty-nine who received before undergoing procedures were enrolled this retrospective study. Of 39 patients, 10 multiple times for total 53 regimens treatment. Changes platelet counts, effects treatment, analyzed. Results The median count increased significantly from 4.5×104/μL 7.2×104/μL procedure (p<0.01), 49 (92%) succeeded without needing transfusions. In repeatedly, following second administration lusutrombopag, similar between first administration. A multivariate analysis identified absence diabetes mellitus (odds ratio, 5.56 presence; p=0.04) as significant independent predictor Conclusion counts disease, making it possible receive produced identical when was repeated. might be decreased mellitus.